Kedudukan dalam Saham
#39567
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Perubahan (1 hari)
-7.14%
Perubahan (1 tahun)
-89.24%
Perdagangan Oxurion N.V. (OXUR)
Harga OXUR dengan permodalan pasaran b
Modal pasaran bagi Oxurion N.V.(OXUR)
Modal Pasaran: $434.03K
Sehingga August 2026, Oxurion N.V. mempunyai modal pasaran sebanyak $434.03K. Ini menjadikan Oxurion N.V. syarikat ke-39567th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Oxurion N.V. dari 2006 hingga 2026
OXUR berbanding dengan 5 teratas yang paling popular stocks
| Harga OXUR |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.470T
|
+1,260,186,454.81%
|
|
|
|
|
$4.467T
|
+1,029,217,230.28%
|
|
|
|
|
$4.174T
|
+961,782,373.59%
|
|
|
|
|
$3.700T
|
+852,501,128.88%
|
|
|
|
|
$2.854T
|
+657,643,093.76%
|
